New drug access program offers hope for lewy body dementia patients

NCT ID NCT06961760

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times

Summary

This program gives people with mild-to-moderate dementia with Lewy bodies access to an experimental drug called CT1812 (Zervimesine) for up to one year. It is designed for patients who either completed a related study or are referred by their doctor and meet specific health criteria. The goal is to monitor long-term safety and see how well the drug works in everyday life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Banner Sun Health Research Institute

    Sun City, Arizona, 85351, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Mayo Clinic - Rochester

    Rochester, Minnesota, 55905, United States

  • Ohio State University Wexner Medical Center (OSUWMC)

    Columbus, Ohio, 43210, United States

  • Stanford Neuroscience Heath Center

    Palo Alto, California, 94304, United States

  • Summit Headlands LLC

    Portland, Oregon, 97210, United States

  • University of Colorado Denver - Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • University of Miami - Department of Neurology

    Boca Raton, Florida, 33433, United States

Conditions

Explore the condition pages connected to this study.